JP2016520548A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520548A5
JP2016520548A5 JP2016506307A JP2016506307A JP2016520548A5 JP 2016520548 A5 JP2016520548 A5 JP 2016520548A5 JP 2016506307 A JP2016506307 A JP 2016506307A JP 2016506307 A JP2016506307 A JP 2016506307A JP 2016520548 A5 JP2016520548 A5 JP 2016520548A5
Authority
JP
Japan
Prior art keywords
cancer
antibody
inducing
composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016506307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520548A (ja
JP6361039B2 (ja
Filing date
Publication date
Priority claimed from US13/966,450 external-priority patent/US9315567B2/en
Application filed filed Critical
Priority claimed from PCT/US2013/075201 external-priority patent/WO2014163684A1/en
Publication of JP2016520548A publication Critical patent/JP2016520548A/ja
Publication of JP2016520548A5 publication Critical patent/JP2016520548A5/ja
Application granted granted Critical
Publication of JP6361039B2 publication Critical patent/JP6361039B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016506307A 2013-04-03 2013-12-14 疾患に対する免疫反応を誘導するための併用療法 Active JP6361039B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361807998P 2013-04-03 2013-04-03
US61/807,998 2013-04-03
US13/966,450 US9315567B2 (en) 2012-08-14 2013-08-14 T-cell redirecting bispecific antibodies for treatment of disease
US13/966,450 2013-08-14
PCT/US2013/075201 WO2014163684A1 (en) 2013-04-03 2013-12-14 Combination therapy for inducing immune response to disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018085760A Division JP2018135371A (ja) 2013-04-03 2018-04-26 疾患に対する免疫反応を誘導するための併用療法

Publications (3)

Publication Number Publication Date
JP2016520548A JP2016520548A (ja) 2016-07-14
JP2016520548A5 true JP2016520548A5 (cg-RX-API-DMAC10.html) 2016-12-22
JP6361039B2 JP6361039B2 (ja) 2018-07-25

Family

ID=51658778

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016506307A Active JP6361039B2 (ja) 2013-04-03 2013-12-14 疾患に対する免疫反応を誘導するための併用療法
JP2018085760A Pending JP2018135371A (ja) 2013-04-03 2018-04-26 疾患に対する免疫反応を誘導するための併用療法
JP2019038757A Expired - Fee Related JP6767029B2 (ja) 2013-04-03 2019-03-04 疾患に対する免疫反応を誘導するための併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018085760A Pending JP2018135371A (ja) 2013-04-03 2018-04-26 疾患に対する免疫反応を誘導するための併用療法
JP2019038757A Expired - Fee Related JP6767029B2 (ja) 2013-04-03 2019-03-04 疾患に対する免疫反応を誘導するための併用療法

Country Status (5)

Country Link
EP (1) EP2981281B1 (cg-RX-API-DMAC10.html)
JP (3) JP6361039B2 (cg-RX-API-DMAC10.html)
CN (2) CN105073128A (cg-RX-API-DMAC10.html)
CA (1) CA2899577C (cg-RX-API-DMAC10.html)
WO (1) WO2014163684A1 (cg-RX-API-DMAC10.html)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US10570202B2 (en) 2014-02-04 2020-02-25 Pfizer Inc. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
ES2978993T3 (es) * 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
ES2913205T3 (es) 2014-05-13 2022-06-01 Bioatla Inc Proteínas biológicas activas condicionalmente
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR20170132171A (ko) 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 pd­1 / pd­l1 저해제
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
ES2984656T3 (es) * 2015-05-13 2024-10-30 Ablynx Nv Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
US20180312561A1 (en) * 2015-06-12 2018-11-01 Immungene, Inc. Focused interferon immunotherapy for treatment of cancer
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
RU2766890C2 (ru) 2015-06-16 2022-03-16 Мерк Патент Гмбх Комбинированные способы лечения антагонистами pd-l1
CA2986066A1 (en) * 2015-06-30 2017-01-05 Boehringer Ingelheim International Gmbh Multi-specific binding proteins
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ai治療公司 使用阿吡莫德治療癌症之方法
BR112018012352A2 (pt) 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
EP3400218A4 (en) 2016-01-08 2019-09-18 Euclises Pharmaceuticals, Inc. COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
ES3056995T3 (en) * 2016-04-13 2026-02-25 Vivia Biotech Sl Ex vivo bite-activated t cells
US20190282679A1 (en) * 2016-04-18 2019-09-19 Rima McLeod Toxoplasma gondii vaccines and their use
CN109790581A (zh) * 2016-04-27 2019-05-21 米拉迪克斯有限公司 Kras-变体癌症患者的基于免疫的治疗
RU2725292C2 (ru) * 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
EP3450460B1 (en) * 2016-04-29 2023-07-12 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
US20190147976A1 (en) * 2016-05-05 2019-05-16 Nantomics, Llc Checkpoint failure and methods therefor
CA3026563C (en) 2016-06-10 2023-11-28 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
CN105943510A (zh) * 2016-06-13 2016-09-21 佛山市腾瑞医药科技有限公司 一种艾代拉利司制剂及其应用
US12653874B2 (en) 2016-06-30 2026-06-16 Immunitybio, Inc. Nant cancer vaccine
KR20210010678A (ko) * 2016-06-30 2021-01-27 난트 홀딩스 아이피, 엘엘씨 난트 암 백신
US20190170752A1 (en) * 2016-08-08 2019-06-06 Beigene, Ltd. Method for predicting efficacy of immune checkpoint inhibitors in cancer patients
EP3515951B1 (en) 2016-09-23 2024-02-28 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
US12188935B2 (en) 2016-09-30 2025-01-07 Centre National De La Recherche Scientifique Method for the evaluation of antiretroviral therapy (ART) effectiveness in HIV-1 CD4+CD89+ cellular reservoirs
EP3519822B1 (fr) * 2016-09-30 2021-05-12 Centre National De La Recherche Scientifique Marqueurs cellulaires
BR112019006504A2 (pt) 2016-10-06 2019-06-25 Pfizer Inc. regime de dosagem de avelumabe para o tratamento de câncer
JP6948685B2 (ja) * 2016-11-04 2021-10-13 国立大学法人金沢大学 抗癌作用増強剤及び癌治療支援方法
EP3534935A1 (en) * 2016-11-04 2019-09-11 Vaximm AG Wt1 targeting dna vaccine for combination therapy
US20200062836A1 (en) * 2016-11-16 2020-02-27 Eli Lilly And Company THERAPY FOR METATASTIC COLORECTAL CANCER USING ANTI-VEGFR-2 and ANTI-VEGF-D ANTIBODIES
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
JP2020508323A (ja) * 2017-02-23 2020-03-19 ラクテン メディカル インコーポレイテッド 光免疫療法のための治療用組成物および関連する方法
EP3601357A1 (en) * 2017-03-29 2020-02-05 Glycotope GmbH Multispecific antibody constructs binding to muc1 and cd3
KR20190136076A (ko) * 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
CA3069672A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
CA3073953A1 (en) 2017-08-31 2019-03-07 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
JP7236385B2 (ja) * 2017-09-26 2023-03-09 中外製薬株式会社 医薬組成物
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
CN109954131B (zh) * 2017-12-14 2023-05-02 深圳市中科艾深医药有限公司 一种肿瘤坏死因子相关凋亡诱导配体拮抗剂作为脓毒血症治疗药物的应用
JP7555270B2 (ja) * 2018-02-13 2024-09-24 プレシジョン バイオロジックス、インコーポレイテッド Treg細胞を標的とするための方法及び組成物
KR102373502B1 (ko) 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
EP3569617A1 (en) * 2018-05-18 2019-11-20 Trion Research GmbH Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
US20220002398A1 (en) * 2018-06-07 2022-01-06 Oncoone Research & Development Gmbh ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
JP7541930B2 (ja) * 2018-06-29 2024-08-29 ジーオー セラピューティクス,インコーポレイテッド 抗グリコmuc1抗体およびその使用
CN113164445A (zh) * 2018-08-02 2021-07-23 得克萨斯系统大学评议会 Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病
MX2021002302A (es) * 2018-08-29 2021-04-28 Chemocentryx Inc Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control.
AU2019354105A1 (en) * 2018-10-04 2021-04-29 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-CD37 antibodies
CN113227121A (zh) * 2018-10-05 2021-08-06 Rnagene公司 通过特异性结合至靶细胞具有增强的多种免疫功能的嵌合抗原及其用途
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12624086B2 (en) 2018-10-31 2026-05-12 Mayo Foundation For Medical Education And Research Materials and methods for treating cancer
JP7521163B2 (ja) 2018-12-19 2024-07-24 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ 抗ceacam6及びtim3抗体の医薬組み合わせ
CN110438081B (zh) * 2018-12-27 2023-04-14 重庆医药高等专科学校附属第一医院 人套细胞淋巴瘤恶性克隆细胞株及其建立方法和应用
WO2020152122A1 (en) * 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
KR20220012313A (ko) 2019-05-23 2022-02-03 벨로스바이오 인코포레이티드 항-ror1/항-cd3 이중특이적 결합 분자
KR20210021861A (ko) * 2019-08-19 2021-03-02 (주)제노팜 사람 표피성장인자수용체 2 양성 암을 치료하기 위한 인터페론-베타 변이체 면역사이토카인의 용도 및 환자 선별 방법
EP4061487A4 (en) * 2019-11-19 2023-12-20 Rootpath Genomics, Inc. COMPOSITIONS AND METHODS FOR IDENTIFYING T CELL RECEPTOR
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
CA3172949A1 (en) * 2020-03-27 2021-09-30 Robert Z. Orlowski Monoclonal antibodies targeting hsp70 and therapeutic uses thereof
US20230241237A1 (en) * 2020-04-16 2023-08-03 Emory University Immune Cell Redirecting Compositions and Therapeutic Uses Thereof
CN111705013B (zh) * 2020-06-02 2021-12-07 华中农业大学 一种牛支原体Mbov_0570基因突变株及其应用
CA3182769A1 (en) * 2020-06-15 2021-12-23 Andrew P. Mazar Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease
CN111850002B (zh) * 2020-06-22 2022-04-19 华中农业大学 牛支原体分泌蛋白MbovP570的应用
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
US20240092931A1 (en) * 2020-08-24 2024-03-21 Janux Therapeutics, Inc. Antibodies targeting trop2 and cd3 and uses thereof
JP2023539525A (ja) * 2020-09-02 2023-09-14 ジェンマブ エー/エス 抗体療法
EP4247412A4 (en) * 2020-11-18 2024-10-23 University of Florida Research Foundation, Inc. Materials and methods for sensitizing tumors to immune response
JP2022157223A (ja) * 2021-03-31 2022-10-14 国立大学法人神戸大学 抗ガン剤効果増強剤
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
CN115671253B (zh) * 2021-07-30 2024-02-27 河北菲尼斯生物技术有限公司 Se-dr亲和肽在制备治疗风湿疾病的药物中的用途
CN118541392A (zh) * 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN114209652B (zh) * 2021-12-29 2022-08-09 中山大学附属第一医院 一种微环境nk细胞免疫调控递送系统及其制备方法和应用
CN114300089B (zh) * 2022-01-04 2024-09-03 哈尔滨医科大学 一种中晚期结直肠癌治疗方案决策算法
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
EP4482865A1 (en) * 2022-02-24 2025-01-01 Xencor, Inc. Anti-cd28 x anti-trop2 antibodies
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
JP2025512426A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ, インコーポレイテッド 腫瘍抗原発現がんを治療するための併用療法
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024012513A1 (en) * 2022-07-13 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024097812A1 (en) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Therapy for treating bladder cancer
CN115975026B (zh) * 2022-11-15 2024-06-25 青海大学 一种抗多房棘球蚴原头节的纳米抗体、重组菌及其应用
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ, インコーポレイテッド Kras調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
WO2025027090A1 (en) * 2023-07-31 2025-02-06 Danmarks Tekniske Universitet Inhibitors of cell envelope proteinases from lactic acid bacteria
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
CN116874606B (zh) * 2023-09-08 2023-11-24 益科思特(北京)医药科技发展有限公司 一种靶向trop2和cd3的双特异性抗体及其制备方法与应用
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025184896A1 (zh) * 2024-03-08 2025-09-12 四川大学华西医院 增强免疫检查点抑制剂抗肿瘤疗效的方法和药物及其应用
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors
CN120518757B (zh) * 2025-07-23 2025-09-23 中国人民解放军军事科学院军事医学研究院 一种聚乙二醇化多价抗西尼罗病毒单链抗体
CN121293363B (zh) * 2025-12-09 2026-04-21 上海玄言生物科技有限公司 一种靶向cd14和cd3的双功能t细胞衔接器及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
US8481041B2 (en) * 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
AU2006262231B2 (en) * 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
NZ568016A (en) * 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
WO2010017500A2 (en) * 2008-08-08 2010-02-11 Immunomedics, Inc. Anti-pancreatic cancer antibodies
CA2772572A1 (en) * 2009-08-31 2011-03-03 Ibc Pharmaceuticals, Inc. Bispecific immunocytokine dock-and-lock (dnl) complexes and therapeutic use thereof
US9249217B2 (en) * 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
WO2012143524A2 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
BR112014002353B1 (pt) * 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease

Similar Documents

Publication Publication Date Title
JP6767029B2 (ja) 疾患に対する免疫反応を誘導するための併用療法
JP6759508B2 (ja) Trop−2発現細胞に対する免疫応答を誘発することによる疾患治療
US10662252B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
US10669338B2 (en) Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1
US10245321B2 (en) Combination therapy for inducing immune response to disease
US10111954B2 (en) Combination therapy for inducing immune response to disease
US10131712B2 (en) Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
US20160361360A1 (en) Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
WO2018217227A1 (en) Novel anti-pd-1 checkpoint inhibitor antibodies that block binding of pd-l1 to pd-1
JP2012500286A5 (cg-RX-API-DMAC10.html)
IL278350B (en) J-chain qualified
WO2017210058A1 (en) Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors
US20220288118A1 (en) Depletion regimes for engineered t-cell or nk-cell therapy
EP3599250A1 (en) Antibody conjugate, and related pharmaceutical composition and application